Piramal Pharma (Mid Cap - High Growth) Share Target 2025, 2026 To 2035
|
Piramal Pharma Limited |
|||
|
Price: ₹242.30 (+0.57%) | ||
| 52 Week Low: ₹114.35 52 Week High: ₹307.90 |
|||
| Market Capital: 19,460.56 Crore (Midcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Piramal Pharma Share Price Target For 2025
- 1.1.1: Piramal Pharma Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Piramal Pharma Share Price Target For 2026
- 1.2.1: Piramal Pharma Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Piramal Pharma Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Piramal Pharma Brief Company Overview
- 4: Piramal Pharma Financial Performance
- 4.0.1: Is Piramal Pharma A Good Buy For Long Term?
Piramal Pharma, a Mid Cap company in the Drug Manufacturers—Specialty & Generic Industry has delivered 67.1% returns in 1-year showing 14.7% quarterly revenue growth with 0.2% profit margin, making it a High Growth stock.
To predict the Piramal Pharma's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Piramal Pharma Share Price Target For 2025
The line chart displays the monthly closing prices of Piramal Pharma with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Piramal Pharma shares in 2025, see the table below.
Piramal Pharma Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 277.6 (+14.56%) | Price Action: 03 Dec 2024 High |
| 2025 Target 2 | 274.74 (+13.38%) | Price Action: Oct 2024 High |
| 2025 Target 1 | 271.45 (+12.03%) | Price Action: 01 Nov 2024 Low |
| Current Price | 242.30 | Piramal Pharma's share price as of 22 Jan 2025 |
| Stop Loss 1 | 229.0 (-5.49%) | Price Action: 07 Oct 2024 High |
| Stop Loss 2 | 226.49 (-6.53%) | Price Action: 09 Oct 2024 High |
| Stop Loss 3 | 224.01 (-7.55%) | Price Action: 24 Oct 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Piramal Pharma is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹247.75 serves as the nearest technical reference point.
Historical Returns: 3-month: -10.27% | 6-month: +36.94% | 1-year: +67.12%
Piramal Pharma Share Price Target For 2026
The line chart displays the monthly closing prices of Piramal Pharma with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Piramal Pharma shares in 2026, see the table below.
Piramal Pharma Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 413.9 (+70.81%) | Price Action: Chart |
| 2026 Target 2 | 406.18 (+67.63%) | Price Action: Chart |
| 2026 Target 1 | 402.16 (+65.97%) | Fibonacci Extension Level 64.90% |
| Current Price | 242.30 | Piramal Pharma's share price as of 22 Jan 2025 |
| Stop Loss 1 | 199.55 (-17.64%) | Technical Indicator: MA200 |
| Stop Loss 2 | 196.7 (-18.82%) | Price Action: 03 Sep 2024 High |
| Stop Loss 3 | 193.5 (-20.14%) | Price Action: 23 Aug 2024 High |
Long-Term Technical Outlook
52-Week Range Analysis: Piramal Pharma is currently trading at 66.1% of its 52-week range (₹114.35 - ₹307.9).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +67.12% | 3-year: NA | 5-year: NA
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Piramal Pharma Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹242.30 | ||
| 2025 | ₹381.92 | +57.62% | ₹387.65 |
| 2026 | ₹484.00 | +26.72% | ₹491.26 |
| 2027 | ₹737.20 | +52.31% | ₹748.26 |
| 2028 | ₹972.72 | +31.94% | ₹987.31 |
| 2029 | ₹1,300.88 | +33.73% | ₹1,320.39 |
| 2030 | ₹1,605.15 | +23.38% | ₹1,629.23 |
| 2031 | ₹1,942.23 | +20.99% | ₹1,971.36 |
| 2032 | ₹2,419.71 | +24.58% | ₹2,456.01 |
| 2033 | ₹3,031.47 | +25.28% | ₹3,076.94 |
| 2034 | ₹3,649.89 | +20.4% | ₹3,704.64 |
| 2035 | ₹4,478.25 | +22.69% | ₹4,545.42 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Piramal Pharma Brief Company Overview
Piramal Pharma Limited: A Comprehensive Overview Piramal Pharma Limited Piramal Pharma Limited, a subsidiary of Piramal Enterprises Limited, is a leading pharmaceutical company incorporated in 2020 and based in Mumbai, India. The company boasts a diverse portfolio of...
pharmaceutical products, including injections and HPAPIs. Piramal Pharma Limited is renowned for its commitment to providing high-quality pharma services and upholding industry standards.Piramal Pharma Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 19,460.56 Crore | Market valuation of Piramal Pharma's shares. |
| Revenue (TTM) | 8,171.16 Crore | Total revenue generated by Piramal Pharma over the past twelve months. |
| Net Income (TTM) | +17.82 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +13.07% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +0.21% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+14.7% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+102.1% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
59.53 | Company's total debt divided by total shareholder equity. |
| Total Debt | 4,710.15 Crore | Sum of Piramal Pharma's current & long-term financial obligations. |
| Total Cash | 627.25 Crore | Total amount of liquid funds available to Piramal Pharma. |
Is Piramal Pharma A Good Buy For Long Term?
Piramal Pharma's recent financial performance indicates strong growth potential. Its revenue surge of 14.7% and net income expansion of 102.1% in the past quarter reflect a positive trend. The company's stable profit margin of 0.21% and improved cash flow position further enhance its investment appeal. While it does carry a substantial debt of 4,710.15 Crore, this is offset by its strong revenue generation and healthy cash reserves. Overall, Piramal Pharma presents a compelling opportunity for long-term investors seeking growth and potential value appreciation.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
